{"page_content": "Page 3\nKARYOPHARM THERAPEUTICS ESG SUMMARY\n\u00a92023 Karyopharm Therapeutics Inc. All rights reserved.OUR PEOPLE\nSince the Company\u2019s founding in 2008, we have grown into \nan international organization with corporate headquarters in \nNewton, Massachusetts and offices in Israel and the European \nUnion. We support a culture of innovation, courage, alignment \nand accountability, resilience and energy (ICARE) and foundational \nbehaviors including mutual respect, integrity, honesty, compliance \nand ethics. \nOur highly qualified, diverse, and experienced team, which includes \nscientists, physicians and professionals across sales, marketing, \nmanufacturing, regulatory, legal, finance and other important \nfunctions are critical to our success. \nFor U.S. based employees, we offer a comprehensive and \ncompetitive total rewards package that includes:\n\u2022 Basic Life, Accidental Death and Dismemberment  \nand Disability programs 100% paid \n\u2022 Medical, Dental, and Vision plans \n\u2022 Voluntary Life Insurance 100% paid \u2022 Employee Stock Purchase Plan available  \nto all eligible employees \n\u2022 Equity awards \n\u2022 Annual Bonus Program \n\u2022 Flexible Spending Account \n\u2022 401(k) Retirement Savings Plan  \n(with up to a 4% match)\n\u2022 Employee Assistance Program \n\u2022 Tuition Assistance Program \n\u2022 Employee Referral Bonus \n\u2022 Paid Time Off \nFor the third year in a row, we have been named by Comparably \nfor Best Company Compensation for small and midsize companies \nand best in Health and Wellness by Nation\u2019s Best.\nInvestments in training, development and engagement for  \nall employees include: \n\u2022 Annual Goal Setting and Development Reviews \n\u2022 Employee Engagement Survey \n\u2022 Quarterly Employee Recognition Program \n\u2022 Dialogue on Diversity initiatives to allow for open discussion on \nDiversity, Equity and Inclusion \n\u2022 LinkedIn Learning memberships \nAt Karyopharm we live by our ICARE values in order to provide \naccess to novel therapies and ongoing support to patients living \nwith cancer. This common value proposition allows us to work \ncollaboratively, efficiently, and in sync as a global team with a \nsingular focus on treatments that change lives. \n\u2022 Our statement on our commitment to diversity and equality \ncan be found here: Statement on Commitment to Diversity and \nEquality. \n\u2022 Our equal employment opportunity statement can be found \nhere: Karyopharm Therapeutics Equal Employment Opportunity \nStatement Link . \n\u2022 All employees are trained annually on our Code of Ethics \nand Business Conduct  as well as sexual-harassment and \ndiscrimination.\n\u2022 As of February 2023, approximately 57% of our workforce and \n50% of our Senior Leadership Team (VP and above) are women \nand over 39% of employees identify as part of a minority group. \n", "metadata": {"source": "NASDAQ_KPTI_2023.pdf", "page": 2, "parser": "pypdf", "split_method": "page", "run_time": "2024-05-29 08:35:04"}, "type": "Document"}